Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Lung15: Dato-DXd +/- Osimertinib vs Platinum-based Chemotherapy in EGFR-mutated Advanced NSCLC
NCT06417814Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2024
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 24
01
Overview
A Phase 3 trial of datopotamab deruxtecan in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Oct 2024; status: active, not recruiting.
02
Drugs
datopotamab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06417814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06417814.